The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity

The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity

Background: The marine-derived kinase inhibitor fascaplysin down-regulates the PI3K pathway in cancer cells. Since this pathway also plays an essential role in platelet signaling, we herein investigated the effect of fascaplysin on thrombosis. Methods: Fascaplysin effects on platelet activation, pla...

Full description

Bibliographic Details
Main Authors:	Emmanuel Ampofo, Thomas Später, Isabelle Müller, Hermann Eichler, Michael D. Menger, Matthias W. Laschke
Format:	Article
Language:	English
Published:	MDPI AG 2015-11-01
Series:	Marine Drugs
Subjects:	fascaplysin thrombosis platelets GPIIb/IIIa P-selectin leukocytes CD11b dorsal skinfold chamber
Online Access:	http://www.mdpi.com/1660-3397/13/11/6774

Similar Items

Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors
by: Chen H, et al.
Published: (2018-07-01)

The Marine-Derived Triterpenoid Frondoside A Inhibits Thrombus Formation
by: Emmanuel Ampofo, et al.
Published: (2020-02-01)

Lack of influence of the COX inhibitors metamizol and diclofenac on platelet GPIIb/IIIa and P-selectin expression <it>in vitro</it>
by: Gröschel Werner, et al.
Published: (2004-04-01)

GPIbα is the driving force of hepatic thrombopoietin generation
by: Danielle Karakas, et al.
Published: (2021-05-01)

Response of human blood platelets to preparations from leaves of Paulownia Clon in Vitro 112
by: Natalia Sławińska, et al.
Published: (2023-09-01)

First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction
by: Dean J. Kereiakes, et al.
Published: (2020-09-01)

Platelet activity and hypercoagulation in type 2 diabetes
by: Lesha Pretorius, et al.
Published: (2018-11-01)

The effects of hydrogen sulfide on platelet–leukocyte aggregation and microvascular thrombolysis
by: Eberhard Grambow, et al.
Published: (2017-07-01)

Fascaplysin Sensitizes Anti-Cancer Effects of Drugs Targeting AKT and AMPK
by: Taek-In Oh, et al.
Published: (2017-12-01)

Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells
by: Tyson W. Lager, et al.
Published: (2018-11-01)

Brassinin Promotes the Degradation of Tie2 and FGFR1 in Endothelial Cells and Inhibits Triple-Negative Breast Cancer Angiogenesis
by: Yuan Gu, et al.
Published: (2022-07-01)

Triggering of Suicidal Erythrocyte Death by Fascaplysin
by: Morena Mischitelli, et al.
Published: (2016-09-01)

Improved Vascularization and Survival of White Compared to Brown Adipose Tissue Grafts in the Dorsal Skinfold Chamber
by: Andrea Weinzierl, et al.
Published: (2021-12-01)

Intravital Fluorescence Videomicroscopy to Study Tumor Angiogenesis and Microcirculation
by: Peter Vajkoczy, et al.
Published: (2000-01-01)

Marine-Derived Lead Fascaplysin: Pharmacological Activity, Total Synthesis, and Structural Modification
by: Chao Wang, et al.
Published: (2023-03-01)

Pseudotrombocitopenia Pseudothrombocytopenia
by: Luci Maria Sant'Ana Dusse, et al.
Published: (2004-10-01)

Development of the Integrated Computer Simulation Model of the Intracellular, Transmembrane, and Extracellular Domain of Platelet Integrin α<sub>IIb</sub>β<sub>3</sub> (Platelet Membrane Glycoprotein: GPIIb–IIIa)
by: Masamitsu Nakayama, et al.
Published: (2024-01-01)

Association of Antiretroviral Therapy with Platelet Function and Systemic Inflammatory Response in People Living with HIV: A Cross-Sectional Study
by: Karolina Akinosoglou, et al.
Published: (2023-04-01)

Time-Dependent Dynamics Required for the Degradation and Restoration of the Vascular Endothelial Glycocalyx Layer in Lipopolysaccharide-Treated Septic Mice
by: Akane Shinohara, et al.
Published: (2021-09-01)

Identification of three novel pathogenic ITGA2B and one novel pathogenic ITGB3 mutations in patients with hereditary Glanzmann’s thrombasthenia living in Eastern Turkey
by: Kamuran Karaman, et al.
Published: (2021-02-01)

Platelet Activation in Ovarian Cancer Ascites: Assessment of GPIIb/IIIa and PF4 in Small Extracellular Vesicles by Nano-Flow Cytometry Analysis
by: Barbara Bortot, et al.
Published: (2022-08-01)

Secondary immune thrombocytopenic purpura with renal cell carcinoma
by: Shigeaki Nakazawa, et al.
Published: (2019-09-01)

Function of protein kinase CK2 in thrombus formation
by: Emmanuel Ampofo, et al.
Published: (2019-05-01)

Boosting Tissue Vascularization: Nanofat as a Potential Source of Functional Microvessel Segments
by: Andrea Weinzierl, et al.
Published: (2022-02-01)

Arteriosclerosis and the promise of GPIIb/IIIa inhibitors in stroke Arteriosclerosis y nuevas perspectivas de los inhibidores del receptor GPIIb/IIIa en stroke
by: GUSTAVO SAPOSNIK, et al.
Published: (2000-03-01)

Identification of one novel pathogenic ITGB3 mutation and two known mutations in two Chinese pedigrees with hereditary Glanzmann thrombasthenia
by: Zhengjing Lu, et al.
Published: (2020-04-01)

Luminal epithelium in endometrial fragments affects their vascularization, growth and morphological development into endometriosis-like lesions in mice
by: Dilu Feng, et al.
Published: (2014-02-01)

Comparison of the Inhibitory Binding Modes Between the Planar Fascaplysin and Its Nonplanar Tetrahydro-β-carboline Analogs in CDK4
by: Yan Liang, et al.
Published: (2021-02-01)

Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation
by: Thomas Später, et al.
Published: (2018-04-01)

Recent Advances in the Synthesis of the Marine-Derived Alkaloid Fascaplysin and Its Metabolites Homofascaplysins A–C
by: Ramana Reddy Mittapalli, et al.
Published: (2024-04-01)

Study of Structure–Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer Agents
by: Maxim E. Zhidkov, et al.
Published: (2022-03-01)

A New Mild Method for Synthesis of Marine Alkaloid Fascaplysin and Its Therapeutically Promising Derivatives
by: Oleg A. Tryapkin, et al.
Published: (2023-07-01)

Growth Differentiation Factor-15 Correlates Inversely with Protease-Activated Receptor-1-Mediated Platelet Reactivity in Patients with Left Ventricular Assist Devices
by: Maximilian Tscharre, et al.
Published: (2022-04-01)

Estudo experimental do uso de um antagonista do receptor da glicoproteína IIb/IIIa das placentas na prevenção de tromboses em microanastomoses vasculares An experimental study on the use of an antagonist of the platelet glycoprotein IIb/IIIa receptor in the prevention of thrombosis in vascular microanastomoses
by: Márcio Issamu Oide
Published: (2000-06-01)

Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines
by: Barbara Rath, et al.
Published: (2018-10-01)

Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome
by: Antonio de Padua Mansur, et al.

9-Methylfascaplysin Is a More Potent Aβ Aggregation Inhibitor than the Marine-Derived Alkaloid, Fascaplysin, and Produces Nanomolar Neuroprotective Effects in SH-SY5Y Cells
by: Qingmei Sun, et al.
Published: (2019-02-01)

Introduction of direct-acting antiviral agents alters frequencies of anti-GPIIb/IIIa antibody-producing B cells in chronic hepatitis C patients with thrombocytopenia
by: Takashi Satoh, et al.
Published: (2023-12-01)

A comparative study of tirofiban plus enoxaparin versus enoxaparin alone along with dual antiplatelet blockade in the management of patients with non-ST elevation acute coronary syndrome
by: Monika Bhandari, et al.
Published: (2018-01-01)

Feasibility study of incident dark-field video microscope for measuring microcirculatory variables in the mouse dorsal skinfold chamber model
by: Christine Kang, et al.
Published: (2021-02-01)